Testing B7-H3 CAR T cell therapy in children and young adults with brain tumors that came back
Official title: B7-H3.CD28Z.CART in CNS Neoplasms
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a cell therapy for young people whose brain tumor came back or kept growing.
Read our full plain-language summary
What the trial team says
The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors. Recurrent/recurred means a tumor that has gone away and then came back. This cell therapy is called B7- H3.CD28Z.CART, referred to as B7-H3 CAR T cells. B7-H3 is a protein that is over-expressed on many tumor cells, making it a good target for cancer cell therapy. The names of the study investigational therapies involved in this study are: * Fludarabine (a type of chemotherapy) * Cyclophosphamide (a type of chemotherapy) * B7-H3 CAR T cells (a type of cellular therapy)
Key facts
- Registry number
- NCT07390539
- Stage of testing
- Phase 1
- Conditions studied
- Central Nervous System Neoplasms, Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Pediatric, Brain Tumor Adult, Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma, Adult, Medulloblastoma Recurrent, Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Leptomeningeal Disease
Where it is running
This trial lists 2 sites.
-
Massachusetts
- Boston Children's Hospital (Boston)
- Dana-Farber Cancer Institute (Boston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.